NEOSPORIN

Post-LOE

gramicidin; neomycin sulfate; polymyxin b sulfate

Monarch Therapeutics

ANDAOPHTHALMICSOLUTION/DROPS

Approved

Jul 1968

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

NEOSPORIN (gramicidin; neomycin sulfate; polymyxin b sulfate) by Monarch Therapeutics is clinical pharmacology a wide range of antibacterial action is provided by the overlapping spectra of neomycin, polymyxin b sulfate, and gramicidin. First approved in 1968.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY A wide range of antibacterial action is provided by the overlapping spectra of neomycin, polymyxin B sulfate, and gramicidin. Neomycin is bactericidal for many gram-positive and gram-negative organisms. It is an aminoglycoside antibiotic which inhibits protein synthesis by…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on NEOSPORIN at Monarch Therapeutics? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.